Rheumatology Highlights Report

Small Molecular Immunomodulators

	How to Obtain AMA PRA Category 1 Credit™ Watch the activity on your computer or mobile device. Complete the CME posttest (each question must be answered correctly). Login to your account. Complete the credit and evaluation form. Print your personalized CME certificate. Technical Requirements

Release Date:  August 12, 2011
Expiration Date:  August 12, 2012

Estimated Time of Completion:  15 minutes

Description

The Rheumatology Highlights Report is designed for the busy clinician. It provides highlights from key scientific presentations and/or abstracts presented at the international rheumatology meeting. Clinical experts attending this meeting have selected the most significant data to report. Each activity is a 15-minute presentation. Enhancements include downloadable slide sets and audio files, and supporting abstracts with expert commentaries. This series offer two methods of participation: on your computer or mobile device.

Learning Objectives

1. Describe data from the phase 3 clinical trials of tofacitinib therapy in patients with rheumatoid arthritis.
2. Discuss results from phase 2 clinical trials of JAK 1/2 inhibitors, the spleen tyrosine kinase (syk) inhibitor, and the oral sphingosine-1-phosphate (S1P) lyase inhibitor LX3305 in patients with RA.

Target Audience

This activity is directed to rheumatologists, immunologists, rheumatology and immunology fellows, clinical researchers, and rheumatology and immunology allied health professionals, including nurse practitioners and physician assistants.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of  0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, Ohio

Faculty

Vibeke Strand, MD
Biopharmaceutical Consultant
Adjunct Clinical Professor
Division of Immunology, Stanford University
Portola Valley, California

Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), the Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants
for partial support of this activity from:
Amgen, Inc.
Pfizer, Inc.
Abbott Laboratories, Inc.
Genentech and Biogen Idec
UCB, Inc
Human Genome Sciences, Inc.

This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education
and the RJ Fasenmyer Center for Clinical Immunology.

CME Disclaimer